News

The establishment of a US-based R&D and commercial operation represents attainment of one of the Helsinn Group’s corporate strategic goals. Helsinn has appointed Franco Vecchi, who is already

According to the company, the E coli/P aeruginosa PNA FISH is the first-ever test for identifying E coli and P aeruginosa directly from positive blood cultures and the

The Phase II study is a single-blind, placebo-controlled, dose-escalation trial expected to enroll a total of 130 patients with anemia of chronic kidney disease (CKD) who are not

Kapidex (30mg and 60mg) is the first proton pump inhibitor (PPI) with a dual delayed release formulation designed to provide two separate releases of medication. The approval was

Kahr Medical’s drug development pipeline is built around the ‘trans signal converter proteins (TSCP)’ technology, a novel drug technology invented by Mark Tykocinski and licensed from the University

The Office of the Chief Scientist (OCS) has approved this second-year grant to support Modigene’s hGH-CTP program for the period September 2008 through August 2009. The grant will

The acquired assets include all of Cyberkinetics’s rights and regulatory filings for the Andara Oscillating Field Stimulator (OFS) technology for treatment of acute spinal cord injury, an investigational

The new formulation is an immediate-release tablet that combines omeprazole, a proton pump inhibitor, with a mix of buffers. The new drug application (NDA) was submitted under section

The recommendation specifies the use of Revlimid, in combination with dexamethasone, as an option for the treatment of patients with multiple myeloma who have received two or more